The investigators found that elevated mI levels and reduced NAA/mI were associated with higher amyloid-beta plaque load, but not with increased in GFAP-positive astrocytes (indicating changes in astrocyte proliferation) and CD68-positive microglia (indicating neuroinflammation) in a patient cohort with more advanced AD. The gene discussed is GFAP; the disease is Alzheimer disease.